Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study

Background: Combination conversion therapies afforded curative surgery chance for initially unresectable hepatocellular carcinoma (uHCC). This study aimed to evaluate the conversion rate and clinical outcomes of a first-line conversion regimen of lenvatinib combined with transarterial chemoembolizat...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	BJS Open 2022-09, Vol.6 (5)
Hauptverfasser:	Qu, Wei-Feng, Ding, Zhen-Bin, Qu, Xu-Dong, Tang, Zheng, Zhu, Gui-Qi, Fu, Xiu-Tao, Zhang, Zi-Han, Zhang, Xin, Huang, Ao, Tang, Min, Tian, Meng-Xin, Jiang, Xi-Fei, Huang, Run, Tao, Chen-Yang, Fang, Yuan, Gao, Jun, Wu, Xiao-Ling, Zhou, Jian, Fan, Jia, Liu, Wei-Ren, Shi, Ying-Hong
Format:	Artikel
Sprache:	eng
Schlagworte:	Care and treatment Conversion therapy Health aspects Hepatoma Immunotherapy Original
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!